Eric Jonasch
The University of Texas MD Anderson Cancer Center(US)Scripps MD Anderson Cancer Center(US)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Epigenetics and DNA Methylation, Cancer, Hypoxia, and Metabolism, Gene expression and cancer classification, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma(2019)116 cited
- → High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma(2015)84 cited
- → Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death(2015)73 cited
- → Guidelines for surveillance of patients with von Hippel‐Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance(2023)42 cited
- → 39 Safety profile of belzutifan monotherapy in patients with renal cell carcinoma: A pooled analysis of 4 clinical trials(2024)9 cited
- → Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium(2025)5 cited
- → Applications and Issues for Tissue Arrays in Target and Drug Discovery(2004)4 cited
- → The development of an efficient procedure for protein extraction from formalin fixed and paraffin embedded tissues and analysis of its application to reverse phase protein arrays(2010)
- → 20Phase II trial of ivonescimab in patients with advanced clear cell renal cell carcinoma previously treated with immune checkpoint blockade: IVORY trial (NCT06940518)(2025)
- → Additional file 1: of AKT isoform-specific expression and activation across cancer lineages(2018)